☰

Anna M. Calcagno, Ph.D. - Publications

Affiliations: 
2003 University of Kansas, Lawrence, KS, United States 
Area:
Pharmaceutical Chemistry, Pharmacology
Tree Info Similar researchers PubMed Report error

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Gillet JP, Andersen JB, Madigan JP, Varma S, Bagni RK, Powell K, Burgan WE, Wu CP, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman M. A Gene Expression Signature Associated With Overall Survival in Patients With Hepatocellular Carcinoma Suggests a New Treatment Strategy. Molecular Pharmacology. PMID 26668215 DOI: 10.1124/Mol.115.101360  0.353
2013 Gillet J, Andersen JB, Madigan JP, Varma S, Wu C, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman MM. Abstract 954: Multidrug resistance transcriptome analysis highlights compounds that sensitize resistant hepatocellular carcinoma through increased histone acetylation. Cancer Research. 73: 954-954. DOI: 10.1158/1538-7445.Am2013-954  0.337
2012 Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3197-206. PMID 22492981 DOI: 10.1158/1078-0432.Ccr-12-0056  0.362
2011 Calcagno AM. Evolution of drug resistance in cancer: the emergence of unique mechanisms and novel techniques. Molecular Pharmaceutics. 8: 1993. PMID 22136313 DOI: 10.1021/Mp200531M  0.392
2011 Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proceedings of the National Academy of Sciences of the United States of America. 108: 18708-13. PMID 22068913 DOI: 10.1073/Pnas.1111840108  0.421
2011 Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Molecular Pharmaceutics. 8: 2080-8. PMID 21761824 DOI: 10.1021/Mp200240A  0.339
2011 Kiptoo P, Sinaga E, Calcagno AM, Zhao H, Kobayashi N, Tambunan US, Siahaan TJ. Enhancement of drug absorption through the blood-brain barrier and inhibition of intercellular tight junction resealing by E-cadherin peptides. Molecular Pharmaceutics. 8: 239-49. PMID 21128658 DOI: 10.1021/Mp100293M  0.524
2010 Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. Journal of the National Cancer Institute. 102: 1637-52. PMID 20935265 DOI: 10.1093/Jnci/Djq361  0.375
2010 Calcagno AM, Ambudkar SV. Analysis of expression of drug resistance-linked ABC transporters in cancer cells by quantitative RT-PCR. Methods in Molecular Biology (Clifton, N.J.). 637: 121-32. PMID 20419432 DOI: 10.1007/978-1-60761-700-6_6  0.413
2010 Calcagno AM, Ambudkar SV. Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods in Molecular Biology (Clifton, N.J.). 596: 77-93. PMID 19949921 DOI: 10.1007/978-1-60761-416-6_5  0.429
2010 Gillet J, Calcagno AM, Varma S, Davidson B, Elstrand MB, Ganapathi R, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Abstract LB-51: Correlation of expression of MDR-associated genes with outcome in primary ovarian serous carcinoma Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-51  0.353
2010 Calcagno AM, Salcido CD, Gillet J, Wu C, Fostel JM, Mumau M, Gottesman MM, Varticovski L, Ambudkar SV. Abstract LB-261: Cancer stem cell characteristics exhibited by doxorubicin-selected drug-resistant breast cancer cells Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-261  0.377
2009 Orina JN, Calcagno AM, Wu CP, Varma S, Shih J, Lin M, Eichler G, Weinstein JN, Pommier Y, Ambudkar SV, Gottesman MM, Gillet JP. Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Molecular Cancer Therapeutics. 8: 2057-66. PMID 19584229 DOI: 10.1158/1535-7163.Mct-09-0256  0.427
2008 Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Current Molecular Pharmacology. 1: 93-105. PMID 19079736 DOI: 10.2174/1874467210801020093  0.407
2008 Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. British Journal of Cancer. 98: 1515-24. PMID 18382425 DOI: 10.1038/Sj.Bjc.6604334  0.435
2007 Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, Ambudkar SV. Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Molecular Cancer Therapeutics. 6: 3287-96. PMID 18089722 DOI: 10.1158/1535-7163.Mct-07-2005  0.426
2007 Calcagno AM, Kim IW, Wu CP, Shukla S, Ambudkar SV. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Current Drug Delivery. 4: 324-33. PMID 17979652 DOI: 10.2174/156720107782151241  0.367
2006 Seamon JA, Rugg CA, Emanuel S, Calcagno AM, Ambudkar SV, Middleton SA, Butler J, Borowski V, Greenberger LM. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Molecular Cancer Therapeutics. 5: 2459-67. PMID 17041089 DOI: 10.1158/1535-7163.Mct-06-0339  0.382
2006 Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Molecular Pharmaceutics. 3: 87-93. PMID 16686373 DOI: 10.1021/Mp050090K  0.439
2005 Wu CP, Calcagno AM, Hladky SB, Ambudkar SV, Barrand MA. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). The Febs Journal. 272: 4725-40. PMID 16156793 DOI: 10.1111/J.1742-4658.2005.04888.X  0.368
2005 Calcagno AM, Fostel JM, Orchekowski RP, Alston JT, Mattes WB, Siahaan TJ, Ware JA. Modulation of cell adhesion molecules in various epithelial cell lines after treatment with PP2. Molecular Pharmaceutics. 2: 170-84. PMID 15934778 DOI: 10.1021/Mp0499003  0.546
2005 Calcagno AM, Siahaan TJ. Physiological, Biochemical, and Chemical Barriers to Oral Drug Delivery Drug Delivery: Principles and Applications. 15-27. DOI: 10.1002/0471475734.ch2  0.465
2004 Calcagno AM, Fostel JM, Reyner EL, Sinaga E, Alston JT, Mattes WB, Siahaan TJ, Ware JA. Effects of an E-cadherin-derived peptide on the gene expression of Caco-2 cells. Pharmaceutical Research. 21: 2085-94. PMID 15587932 DOI: 10.1023/B:Pham.0000048201.00143.72  0.541
2002 Makagiansar IT, Yusuf-Makagiansar H, Ikesue A, Calcagno AM, Murray JS, Siahaan TJ. N-cadherin involvement in the heterotypic adherence of malignant T-cells to epithelia. Molecular and Cellular Biochemistry. 233: 1-8. PMID 12083363 DOI: 10.1023/A:1015556625038  0.51
Show low-probability matches.